Memorial Sloan Kettering Cancer Center
Presentation To The GIST Cancer Research Fund
March 30, 2016
GIST Cancer Research Fund
March 30, 2016
The 2016 GCRF Conference and Luncheon at Oregon Health and Science University’s Knight Cancer Institute was held on May 10, 2016. The labs of Dr. Michael Heinrich, Dr. Christopher Corliss and Dr. Brian Druker are relentless in their dedication to advancing treatment options for patients with gastrointestinal stromal tumors (GIST) and other cancers. The teams are actively working on a variety of projects that are yielding promising results:
The search for a master key
Strategies to decrease KIT production
Identifying new types of GIST
Establishing model systems for SDH-deficient GIST to test new strategies
Dr. Michael Heinrich gave a presentation which include a review of the the projects he and his team of researchers are currently working on at OHSU.
We would like to extend our sincere gratitude to everyone who participated in the 2016 Annual GCRF Conference and Luncheon. It was wonderful to see so many of you and we hope you found a sense of community, patient support and helpful information at this event. Additionally, we want to thank the GCRF for their incredibly generous donation. With your amazing fundraising efforts, we are able to continue to work hard to find a cure for this devastating disease.
Please click on the following link to view the presentations from the Conference:
Video of Dr. Heinrich’s Research Presentation
Please Attend the: GIST Cancer Research Fund Presentation, Wednesday, March 30, 2016 at 3pm at Rockefeller Research Laboratories, Room 104. Speakers: Cristina R. Antonescu, MD, “Update in Pediatric and Wild Type GIST Research” Ping Chi, MD, PhD, “Clinical Experience of
Targeting ETV1 in Advanced GIST” Ronald P. DeMatteo, MD, FACS, “Immune Therapy for GIST” Please RSVP by Friday, March 25 to Audrey Williams Email: email@example.com • Telephone: 646-227-3531
What is a cialis coupon Generic:
A drug product that is comparable to a brand/reference listed drug product in dosage, viagra or cialis form, generic tadalafil strength, route of administration, quality and performance characteristics, and intended use.
– generic pharmacy online US Food and Drug Administration (FDA)
Sun Pharma announced the launch of Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec® for indications approved by the FDA) to be used in the U.S. market as of February 1, 2016. Sun Pharma has launched an exclusive patient website www.imatinibrx.com providing detailed information about its Imatinib Mesylate, approved indications, side effects etc. Additionally, generic tadalafil the website features detailed FAQs on the tadalafil online product. Eligible patients can participate in Sun Pharma’s Imatinib Mesylate
Savings Card program by registering online at www.imatinibrx.com or by requesting a savings card from their Oncologist. Sun Pharma will be supplying its Imatinib Mesylate cialis generic Savings Cards to over 4,500 Oncologists.
Date: Saturday, April 16, 2016
Time: 11 AM – 1 PM • 2 Miles
Place: Sarg Hubbard Park • 111 S 18th Street, Yakima, Washington 98901
Contact for More Details: Lindsay Hughes Freeburg • 509-969-9518
Join us for Washington State’s Biggest Fundraising Event of the Year!
Please join us & walk to find a cure & bring hope to all GIST patients who are waiting for a miracle.
After the 2 mile walk, a light lunch will be served at noon.
Please give an
hour of your time and save lives!
Gastrointestinal Stromal Tumor (GIST) is a rare cancer affecting the digestive diferença entre tadalafil e sildenafil tract or nearby structures within the abdomen. GI Stromal Tumor, or GIST cancer, is a sarcoma. Sarcomas are cancers that grow from cells of the body’s connective or supportive tissues such as bone, cartilage, tendons, nerves, fat, muscle, synovial tissue (tissue around joints), or blood vessels. (Most cancers are carcinomas, not viagra online sarcomas.) Gist Support
to make a donation, please go to Please Donate. All donations are tax-deductible and 100% goes directly to GIST Cancer Research.
Refractory Solid Tumors
This is an open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antineoplastic activity of BLU-285, administered orally (PO), valacyclovir online pharmacy in adult patients with unresectable GIST or other relapsed or http://cialiscouponedtrial.com/ refractory solid tumors.
The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Ages online viagra prescription Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
For more information click on this link:
Clinical Trial Information
The Annual GIST Cancer Research Luncheon was held http://viagraforwomentreated.com/ on Tuesday, viagra online canada May 12, 2015 in the Robert cialis and molly C. Young, M.D. Pavilion at Fox Chase Cancer Center. A presentation was made by Dr. Margaret von Mehren, M.D., Director, Sarcoma Program, Martin Belinsky, Ph.D., Staff Scientist and Lori Rink, Ph.D., Principal Investigator, on current GIST research and progress being made at cialis online Fox Chase. cialis cancer Tania and Robert Stutman of GCRF presented a check for $100,000 to further http://tadalafilonline200mgdosage.com/ research to find a cure and end this incurable http://cialiscouponedtrial.com/ cancer.
October 3, 2015
Bella Gianna’s • 77 Route 303, Congers, NY
RSVP Tania Stutman
Hilton Garden Hill Nanuet • 270 West Route 59, Nanuet, NY
Use Reservation Gist Cancer Walk Code AME:
$ 96.00 including breakfast
Make your reservation as soon
levitramake dryer I discarding. I scalp it the http://cialiscanada-onlinerx.com/ scents blend mask are next more look.